PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Office of the Paperwork Reduction Area of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

			(V)		on unless it displays a valid	OMB COULD	l numbei
Substitute	for form 1449A/PTO		PADEMARK		ete if Known	9	
INEO		DIGG		Application Number	09/780,041	2	AR R
	RMATION	DISC	LOSURE	Filing Date	2/9/2001	Z	
51A1	TEMENT BY	APP	PLICANT	First Named Inventor	KLEIN et al.	-5	_ ရ
	(use as many sheets	as nacas	agmi)	Group Art Unit	1614	600	303
Classi	1	т т	sary)	Examiner Name	Unknown	/20	2
Sheet	1	of	3	Attorney Docket Number	UF-10293	8	

		r — — — — —		U.S. PATENT DOCUMEN	TS	
Examiner Initials*	Cite No.1	U.S. Patent Do	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant
Ama		5,720,720		Laske et al.	02-24-1998	Figures Appear
Ama		6,027,931		Natsoulis et al.	02-22-2000	
Ama		6,071,889		Weiss et al.	06-06-2000	
					10 2000	
	_					
	\rightarrow					
	-					
	_					
	$-\downarrow$					

FOREIGN PATENT DOCUMENTS									
Examiner	Cite		Foreign Patent Docum	ent					
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant	T ⁶	
Amz	-		WO 99/61066		Avigen, Inc.	12-02-1999	Figures Appear	┼-	
								-	

Examiner			
	Anna mais 2011	Date	
organitate	Anne-Marie Falk	Considered 11/1/02	
*EVAMBIED. T	10.0	- Considered / / 02	

MINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
10/995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. MAR 0 4 2002

	ORGET THE RAPET WORK	TOUGCE	in the party so, no percent			
Substitute for form 1449B				Com		
Substitut	C IOI IOIIII 1445BI	RADE		Application Number	09/780,041	
INFO	ORMATION	DIS	CLOSURE	Filing Date	2/9/2001	
STATEMENT BY APPLICANT				First Named Inventor	KLEIN et al.	
~				Group Art Unit	1614	
	(use as many sheets	s as ne	cessary)	Examiner Name	Unknown	
Sheet	2	of	3	Attorney Docket Number	UF-10293	290

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
	Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	Ama		KLEIN, RONALD, L. et al., "Neuron-Specific Transduction in the Rat Septohippocampal or Nigrostiatal Pathway by Recombinant Adeno-associated Virus Vectors", Experimental Neurology, 1998, 183-194: 150, Academic Press.				
			KLEIN, RONALD, L. et al., "Long-Term Action of Vector-Derived Nerve Growth Factor or Brain-Derived Neurotrophic Factor on Choline Acetyltransferase and TRK Receptor Levels in the Adult Casal Forebrain", Neuroscience, 1999, 815-821: 90-3, Elsevier Science Ltd., Great Britain.				
			KLEIN, RONALD, L. et al., "Prevention of 6-hydroxydopamine-induced Rotational Behavior by BDNF Somatic Gene Transfer", Brain Research, 1999, 314-320, Elsevier Science.				
			PRICE, DONALD, L. et al., "Genetic Neurodegenerative Diseases: The Human Illness and Transgenic Models", Science, 1998, 1079-1083: 282.				
			HSIAO, KAREN, et al., "Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice", Science, 1996, 99-10: 274.				
1			DUFF, KAREN, et al., "Increased Amyloid-β42(43) in Brains of Mice Expressing Mutant Presentilin 1", Nature, 1996, 710-713: 383.				
			PARIMALA, NACHARAJU, et al., "Accelerated Filament Formation From Tau Protein With Specific FTDP-17 Missence Mutation", FEBS Letters, 1999, 195-199:447, Federation of European Biomedical Societies.				
-			POLYMEROPOULOS, MIHAEL, et al., "Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease", Science, 1997, 2045-2047: 276.				
			KRUGER, REJKO, et al., "Ala30Pro Mutation in the Gene Encoding α-synuclein in Parkinson's Disease", Nature Gentics, 1998, 106-108:18.				
			ABELIOVICH, ASA, et al., "Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System", Neuron, 2000, 239-252: 25, Cell Press.				
	Amz		DICKINSON, DENNIS, W., et al., "Tau and Synuclein and Their Role in Neuropathology", Brain Pathaology, 1999, 657-661: 9.				

Examiner	1	2-04	Date	11/1/02
Signature	Anne-marie	sale	Considered	7 70-
Digitatio				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (4) inside this box

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it displays a valid OMB control number.

	Under the Paperwork Reduction Act of 1995, no persons are required to respond to a confection of information unless it displays a value of the paper work Reduction of the Paperwork Re								
Cubatituta	for for MAARINTO	0		Comp	olete if Known	50			
Substitute	for form 449B/PTO	MARIE		Application Number	09/780,041	ÌĊ	/M		
INFO	PRMATION	DIS	CLOSURE	Filing Date	2/9/2001	EN1	R)		
STATEMENT BY APPLICANT				First Named Inventor	KLEIN et al.		၅		
DIII				Group Art Unit	1614	160	200		
	(use as many sheet	ts as ne	cessary)	Examiner Name	Unknown	92	12		
Sheet	3	of	3	Attorney Docket Number	UF-10293	306			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Ī	Examiner Initials* Cite No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	Ama		BUXBAUM, JOSEPH, D., et al., "Expression of APP in the Brains of Transgenic Mice Containing the Entire Human APP Gene", Boichemical and Biophysical Research Communications, 1993, 639-645, 197:2, Academic Press, Inc.				
	1		HIGGINS, L.S., et al., "Transgenic Mouse Brain Histopathology Resembles Early Alzheimer's Disease", Ann Neurol, 1994, 598-607: 35, American Neurological Association.				
1			LAFERLA, FRANK, M., et al., "The Alzheimer's Aβ Peptide Induces Neurodegenration and Apoptotic Cell Death in Trasgenic Mice", Nature Genetics, 1995, 21-30: 9.				
			LAMB, BRUCE, T., et al., "Introduction and Expression of the 400 Kilobase Precursor Amyloid Protein Gene in Transgenic Mice", Nature Genetics, 1993, 22-30: 5.				
			MORAN, PAULA, M., et al., "Age-related Learning Deficits in Transgenic Mice Expressing the 751-Amino Acid Isoform of Human β-amyloid Precursor Protein", Proc. Natl. Acad. Sci., 1995, 5341-5345: 92.				
1			HSIAO, KAREN, K. et al., "Age-related CNS Disorder and Early Death in Transgenic FVB/N Mice Overexpressing Alzheimer Amyloid Precursor Proteins", Neuron, 1995, 1203-1218: 15, Cell Press.				
1			NALBANTOGLU, J., et al., "Impaired Learning and LTP in Mice Expressing the Carboxy Terminus of the Alzheimer Amyloid Precursor Protein", Nature, 1997, 500-505: 387.				
-			LAMB, BRUCE, T. et al., "Altered Metabolism of Familial Alzheimer's Disease-linked Amyloid Precursor Protein Variants in Yeast Artificial Chromosone Transgenic Mice", Human Molecular Genetics, 1997, 1535-1541, 6: 9, Oxford University Press.				
-			KAMMESHEIDT, ANJA, et al, "Depositon of β/ A4 Immunoreactivity and Neuronal Pathology in Transgenic Mice Expressing the Carboxyl-Terminal Fragment of the Alzheimer Amyloid Precursor in the Brain", Proc. Natl. Acad. Sci., 1992, 10857-10861: 89, USA.				
			PEEL, ALYSON, L. and KLEIN, RONALD, L., "Adeno-associated Virus Vectors: Activity and Applications in the CNS", Journal of Neuroscience Methods, 2000, 95-104:98, Elsevier Science.				
			KLEIN, RONALD, L. et al., "NGF Gene Transfer to Intrinsic Basal Forebrain Neurons Increases Cholinergic Cell Size and Protects From Age-Related, Spatial Memory Deficits in Middle-Aged Rats", Brain Research, 2000, 144-151: 875, Elsevier Science.				
	Ama		KLEIN, RONALD, L. et al., "Adeno-Associated Virus Vector Mediated Gene Transfer to Somatic Cells in the Central Nervous System, Advances in Virus Res. Edited by K. Maramorosch, F.A. Murphy, A.J. Shatkin, J.C. Glorioso, 2000, 507-528: 55, Academic Press, SanDiego.				

Examiner		Date	11/1/03
	Anne - marie dalk	Considered	11/1/02
Signature	June -/ were oratic	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

1 Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231